NCT01966302View on ClinicalTrials.gov

Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)

PHASE2CompletedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

June 2, 2019

Study Completion Date

June 2, 2019

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

BPS-314d-MR

15-150 mcg po BID,

Trial Locations (1)

90502

Los Angeles Biomedical research Institute, Torrance

Sponsors

Collaborators (1)

Lung Biotechnology PBC

All Listed Sponsors

collaborator

Lung Biotechnology PBC

INDUSTRY

lead

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

NCT01966302 - Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH) | Biotech Hunter | Biotech Hunter